RecruitMe Clinical Trial

AAML1522: A Phase II, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Activity, Safety and Pharmacokinetics of Lenalidomide (Revlimid) in Pediatric Subjects From 1 to 18 Years of Age with Relapsed or Refractory Acute Myeloid Leukemia
A study for children and adolescents with relapsed or refractory acute myeloid leukemia using study drug Lenalidomide
Sponsor:Children's Hospital of Philadelphia
Enrolling:Male and Female Patients
Age Range:Between 1 and 18 years old
IRB Number:AAAP9858
U.S. Government ID:NCT02538965
Contact: Alice Lee: 212-305-5808 / al2041@cumc.columbia.edu
Additional Study Information:

This study is for children with relapsed or refractory acute myeloid leukemia (rrAML). Acute myeloid leukemia is a fast growing cancer of the blood and bone marrow. This study examines the effects of study drug Lenalidomide on children with rrAML. Lenalidomide is an anti-cancer drug that belongs to a group of drugs known as immunomodulating drugs (IMiDs), a medicine that can modify or regulate the functioning of the immune system. These drugs change how diseased cells in the blood and bone marrow grow. This study also includes testing of bone marrow samples for biomarkers. Biomarkers aresubstances such as gene or protein changes that tell us how the drug is working in your childsbody.

This study is closed
Investigator
Alice Lee, MD
You may be eligible for this study

Place Holder




Who Can I Contact?
For more information, please contact:
Alice Lee
Email: al2041@cumc.columbia.edu
Phone: 212-305-5808